Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2018

01-04-2018 | Original article

Triglyceride metabolism in Japanese kidney transplant recipients

Authors: Makoto Tsujita, Norihiko Goto, Kenta Futamura, Manabu Okada, Takahisa Hiramitsu, Syunji Narumi, Yoshihiko Watarai

Published in: Clinical and Experimental Nephrology | Issue 2/2018

Login to get access

Abstract

Background

Residual cardiovascular risk factors, such as triglyceride (TG), can cause cardiovascular disease. The role of TG metabolism in kidney transplantation remains unclear.

Methods

Sixty-three consecutive stable recipients at 1 year after their kidney transplants were included in the study from January to September 2014 at Nagoya Daini Red Cross Hospital. We performed the cookie test to evaluate TG metabolism. TG, blood sugar, and remnant-like particle cholesterol (RLP-C) were measured at fasting (f) and 2 and 4 h after ingestion. Low- and high-density lipoprotein cholesterol (LDL-C and HDL-C, respectively) and apoB levels were measured at fasting.

Results

Mean TGf and RLP-Cf were 139.4 ± 62.6 and 5.6 ± 3.4 mg/dl, respectively, and were within normal ranges; however, both mean TG 2 and 4 h were >200 mg/dl, and both mean RLP-C 2 and 4 h were >9 mg/dl. A negative correlation was seen between TGf and eGFR (r = −0.48, p < 0.001). TGf positively correlated with RLP-C, non-HDL-C, LDL-C/apoB ratio, and body mass index (r = 0.80, p < 0.001; r = 0.47, p < 0.001; r = 0.48, p < 0.001; and r = 0.38, p = 0.002, respectively). LDL-C levels were controlled because of the use of statin, but LDL-C/apoB ratio levels in 50% of the recipients were <1.2, indicating that the rate of small dense LDL-C in LDL-C had increased.

Conclusion

The prevalence of postprandial hypertriglyceridemia among kidney transplant recipients was high; however, the question of whether or not it should be treated remains unknown.
Literature
1.
go back to reference Kidney Disease Improving Global Outcome (KDIGO). Clinical guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3:263–5.CrossRef Kidney Disease Improving Global Outcome (KDIGO). Clinical guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3:263–5.CrossRef
2.
go back to reference Quaschning T, Mainka T, Nauck M, Rump LC, Wanner C, Kramer-Guth A. Immunosupression enhances atherogenicity of lipid profile after transplantation. Kidney Int Suppl. 1999;71:235–7.CrossRef Quaschning T, Mainka T, Nauck M, Rump LC, Wanner C, Kramer-Guth A. Immunosupression enhances atherogenicity of lipid profile after transplantation. Kidney Int Suppl. 1999;71:235–7.CrossRef
3.
go back to reference Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicenter, randomized, placebo-controlled trial. Lancet. 2003;361:2024–31.CrossRefPubMed Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicenter, randomized, placebo-controlled trial. Lancet. 2003;361:2024–31.CrossRefPubMed
4.
go back to reference Hirata M, Saito M, Miyake S, Hasegawa R. The incremental effect and mechanism of cyclosporine on blood concentration of statins and statin package insert information in Japan. Bull Natl Inst Health Sci. 2005;123:37–40. Hirata M, Saito M, Miyake S, Hasegawa R. The incremental effect and mechanism of cyclosporine on blood concentration of statins and statin package insert information in Japan. Bull Natl Inst Health Sci. 2005;123:37–40.
5.
go back to reference Gardner CD, Fortmann SP, Krauss RM. Association of small low density lipoprotein particles with the incidence of coronary in men and women. JAMA. 1996;276:875–81.CrossRefPubMed Gardner CD, Fortmann SP, Krauss RM. Association of small low density lipoprotein particles with the incidence of coronary in men and women. JAMA. 1996;276:875–81.CrossRefPubMed
6.
go back to reference Lamarche B, Tchernof A, Moorjani AS, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69–75.CrossRefPubMed Lamarche B, Tchernof A, Moorjani AS, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69–75.CrossRefPubMed
7.
go back to reference Hattori Y, Suzuki M, Tsushima T, et al. Development of approximate formula for LDL-cho, LDL-apo B and LDL-cho/LDL-apo B as indices of hyperapobetalipoproteinemia and small dense LDL. Atherosclerosis. 1998;138:289–99.CrossRefPubMed Hattori Y, Suzuki M, Tsushima T, et al. Development of approximate formula for LDL-cho, LDL-apo B and LDL-cho/LDL-apo B as indices of hyperapobetalipoproteinemia and small dense LDL. Atherosclerosis. 1998;138:289–99.CrossRefPubMed
8.
go back to reference Boren J, Matikainen N, Adiels M, Taskinen MR. Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta. 2014;431:131–42.CrossRefPubMed Boren J, Matikainen N, Adiels M, Taskinen MR. Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta. 2014;431:131–42.CrossRefPubMed
9.
go back to reference Norata GD, Grigore L, Raselli S, et al. Post-prandial endothelial dysfunction in hyperglyceridemic subjects: molecular mechanism and gene expression studies. Atherosclerosis. 2009;202:405–14.CrossRef Norata GD, Grigore L, Raselli S, et al. Post-prandial endothelial dysfunction in hyperglyceridemic subjects: molecular mechanism and gene expression studies. Atherosclerosis. 2009;202:405–14.CrossRef
10.
go back to reference Ting HJ, Stice JP, Schaff UY, et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ Res. 2007;100:381–90.CrossRefPubMed Ting HJ, Stice JP, Schaff UY, et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ Res. 2007;100:381–90.CrossRefPubMed
11.
go back to reference Holdass H, Potena L, Saliba F. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? Transplant Rev. 2015;2(29):93–102.CrossRef Holdass H, Potena L, Saliba F. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? Transplant Rev. 2015;2(29):93–102.CrossRef
12.
go back to reference Harano Y, Miyawaki T, Babiki J, et al. Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. Endocr J. 2006;53(2):173–80.CrossRefPubMed Harano Y, Miyawaki T, Babiki J, et al. Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. Endocr J. 2006;53(2):173–80.CrossRefPubMed
13.
go back to reference Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equation for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equation for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
14.
go back to reference Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med. 2003;163:1077–83.CrossRefPubMed Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med. 2003;163:1077–83.CrossRefPubMed
15.
go back to reference Iso H, Naito Y, Sato S, et al. Serum triglyceride and risk of coronary heart disease among japanese men and women. Am J Epidemiol. 2001;153:490–9.CrossRefPubMed Iso H, Naito Y, Sato S, et al. Serum triglyceride and risk of coronary heart disease among japanese men and women. Am J Epidemiol. 2001;153:490–9.CrossRefPubMed
16.
go back to reference Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70–4.CrossRefPubMed Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70–4.CrossRefPubMed
17.
go back to reference Donale EH. Metabolic syndrome in kidney transplantation: management of risk factors. Clin J Am Soc Nephrol. 2011;6:1781–5.CrossRef Donale EH. Metabolic syndrome in kidney transplantation: management of risk factors. Clin J Am Soc Nephrol. 2011;6:1781–5.CrossRef
18.
go back to reference Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentration and lipoprotein metabolism in kidney transplant recipients. Transplant Proc. 2003;35(Suppl 3A):143S–50S.CrossRefPubMed Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentration and lipoprotein metabolism in kidney transplant recipients. Transplant Proc. 2003;35(Suppl 3A):143S–50S.CrossRefPubMed
Metadata
Title
Triglyceride metabolism in Japanese kidney transplant recipients
Authors
Makoto Tsujita
Norihiko Goto
Kenta Futamura
Manabu Okada
Takahisa Hiramitsu
Syunji Narumi
Yoshihiko Watarai
Publication date
01-04-2018
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 2/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1462-1

Other articles of this Issue 2/2018

Clinical and Experimental Nephrology 2/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.